Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition) by Roots Analysis

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this

The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:

  • Phase of development
  • Approved
  • Pre-registration & Phase III
  • Phase II & Phase II/III
  • Type of molecule
  • Cell and gene therapies
  • Monoclonal antibodies
  • Proteins
  • Peptides (recombinant)
  • Vaccines
  • Others
  • Target therapeutic area
  • Autoimmune disorders
  • Blood disorders
  • Bone disorders
  • Genetic disorders
  • Metabolic disorders
  • Neurological disorders
  • Oncological disorders
  • Respiratory disorders
  • Others
  • Type of drug delivery system
  • Large volume wearable injectors
  • Autoinjectors
  • Prefilled syringes
  • Needle-free injectors
  • Drug reconstitution systems

To Request for sample –

  • Revenues from licensing deals
  • Upfront payments
  • Milestone payments
  • Key geographical regions
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030”report features the following companies, which we identified to be key players in this domain:

  • Adocia
  • Ajinomoto Bio-Pharma Services
  • Arecor
  • Alteogen
  • Ascendis Pharma
  • Avadel Pharmaceuticals
  • Camurus
  • Creative BioMart
  • Creative Biolabs
  • Eagle Pharmaceuticals
  • Halozyme Therapeutics
  • MedinCell
  • Xeris Pharmaceuticals
  • Serina Therapeutics

Table of Contents

  1. Preface
  • Executive Summary
  • Introduction
  • Subcutaneous Biologics: Current Market Landscape
  • Case Study: Leading Subcutaneous Biologics
  • Subcutaneous Formulation Technologies: Current Market Landscape
  • Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis
  • Subcutaneous Formulation Technology Developers: Company Profiles
  • Partnerships and Collaborations
  1. Subcutaneous Drug Delivery Systems: Current Market Landscape
  1. Swot Analysis
  1. Market Forecast and Opportunity Analysis
  1. Concluding Remarks
  1. Executive Insights
  1. Appendix 1:  Tabulated Data
  1. Appendix 2: List Of Companies And Organization

To purchase a copy, please visit

Other Recent Offerings

  1. Global Autoinjectors Market (3rd Edition), 2020-2030
  2. Prefilled Syringes Market (5th Edition), 2020-2030
  3. Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030
  4. Large Volume Wearable Injectors Market (4th Edition), 2018-2030

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at

Contact Details

Ben Johnson

+1 (415) 800 3415

Roots Analysis







November 17, 2021

0 responses on "Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition) by Roots Analysis"

    Leave a Message

    Copyrights © 2020 Blavida.
    Skip to toolbar